영남대 연구팀, DNA 항암 면역증강제 개발…생쥐 종양 2.7배 작아
Yeungnam Team Builds a DNA Cancer Immune Booster; Mouse Tumors 2.7 Times Smaller
Part of the October 24, 2026 daily edition
영남대 화학과와 미국 미시간주립대 의과대학 공동 연구팀이 면역세포의 기능을 강화하는 DNA 기반 항암 면역증강제 ’CpG i-dimer’를 개발했습니다. 기존 면역증강제 ’CpG ODN’은 면역세포를 활성화하는 능력이 뛰어나지만, 체내에서 빠르게 분해돼 항암 치료에 쓰기에는 한계가 있었습니다. 연구팀은 산성도(pH) 변화에 반응하는 DNA 구조인 ’i-motif’를 이용해 CpG ODN 두 개를 연결한 나노 구조체를 만들어 체내 안정성을 높였습니다. 생쥐 실험에서도 효과가 확인됐습니다. 악성 흑색종이 생기게 한 생쥐에게 같은 양을 투여하자, 종양 크기는 기존 CpG ODN을 투여한 무리보다 약 2.7배 작았고 생존 기간은 약 1.5배 길었습니다. 연구 성과는 국제학술지 ‘Biomaterials’ 온라인판에 실렸고, 연구팀은 독성 평가와 임상시험을 거쳐 실제 치료제로 개발할 계획입니다.
Translation
A joint research team from Yeungnam University's Department of Chemistry and the College of Medicine at Michigan State University in the US has developed 'CpG i-dimer', a DNA-based anticancer immune booster that strengthens the function of immune cells. The existing immune booster 'CpG ODN' is very good at activating immune cells, but because it breaks down quickly in the body, there were limits to using it in cancer treatment. Using 'i-motif', a DNA structure that responds to changes in acidity (pH), the team made a nanostructure linking two CpG ODN molecules and raised its stability in the body. The effect was confirmed in mouse experiments. When the same amount was given to mice in which malignant melanoma had been induced, tumors were about 2.7 times smaller than in the group given the existing CpG ODN, and survival was about 1.5 times longer. The results were published in the online edition of the international journal 'Biomaterials', and the team plans to develop it into an actual treatment after toxicity evaluation and clinical trials.
Vocabulary
- 면역세포명사 (noun)an immune cell
- 면역증강제명사 (noun)an immune booster, an adjuvant
- 항암명사 (noun)anticancer
- 분해되다동사 (verb)to break down, to be decomposed
- 종양명사 (noun)a tumor
- 투여하다동사 (verb)to administer (a drug)
- 생존 기간명사 (noun)survival time
- 임상시험명사 (noun)a clinical trial
Grammar points
-기에는 한계가 있다there are limits to (doing)
-기에는 한계가 있다 says something falls short for a particular purpose, though it may be good in other ways: 항암 치료에 쓰기에는 한계가 있었습니다, there were limits to using it in cancer treatment. Research news often uses it to set up the problem a new study solves.
Example: 체내에서 빠르게 분해돼 항암 치료에 쓰기에는 한계가 있었습니다.
Because it broke down quickly in the body, there were limits to using it in cancer treatment.
-자when, as soon as (and then a result)
-자 links an action to the result that followed it: 같은 양을 투여하자, 종양 크기는 … 작았고, when the same amount was given, the tumors were smaller. It is a written style, common in reports of experiments.
Example: 악성 흑색종이 생기게 한 생쥐에게 같은 양을 투여하자, 종양 크기는 약 2.7배 작았습니다.
When the same amount was given to mice with induced melanoma, the tumors were about 2.7 times smaller.
N을/를 거쳐after going through N
N을/를 거쳐 names the stages that must come before a goal: 독성 평가와 임상시험을 거쳐, after toxicity evaluation and clinical trials. It shows that the drug is not yet a treatment.
Example: 연구팀은 독성 평가와 임상시험을 거쳐 실제 치료제로 개발할 계획입니다.
The team plans to develop it into an actual treatment after toxicity evaluation and clinical trials.
More in this edition
Culture
Intermediate
안효섭, 셰프복 입고 요리 대회로…JTBC '파이널 테이블' 첫 방송
Ahn Hyo-seop Becomes a Chef in a Cooking Contest: JTBC's 'Final Table' Premieres
Society
Expert
비정규직 867만 명·비중 38.5%…2003년 집계 이후 최대
Non-Regular Workers Hit 8.671 Million, 38.5% of Employees, Highest Since 2003
Economy
Advanced
올리브영, 경주에 한옥 매장…석굴암·첨성대 키링도 판다
Olive Young Opens a Hanok-Style Gyeongju Store With Seokguram Keyrings
Life
Beginner